US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Articles published by Vaxcyte, Inc.

< Previous 1 2 Next >
News headline image
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte to Participate in Upcoming Investor Conferences
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte to Participate in Upcoming Investor Conferences
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Announces Pricing of $550 Million Public Offering
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Advances Adult and Infant Programs for VAX-31, a Potential Best-in-Class, Next-Generation Pneumococcal Conjugate Vaccine
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Doses First Participants in the OPUS Phase 3, Noninferiority Trial Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
News headline image
Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
From Vaxcyte, Inc.
Via GlobeNewswire
Tickers PCVX
< Previous 1 2 Next >